Tags : Untreated

Roche Reports Results of Tecentriq in P-III IMvigor130 Study for

Shots: The P-III IMvigor130 study involves assessing of Tecentriq + platinum-based CT vs platinum based-CT as monothx. in 1213 patients with metastatic urothelial carcinoma (mUC) prior not treated with systemic therapy The P-III IMvigor130 study resulted in meeting its 1EPs of PFS with the reduction in the risk of disease worsening or death, improved OS […]Read More

Eisai Reports Results of Fycompa (perampanel) in P-III FREEDOM Study

Shots: The P-III FREEDOM study (Study 342) results involve assessing of Fycompa (2mg/day & 4mg/day) as monothx.in 89 patients with newly diagnosed or untreated POS aged ≥12 yrs. The P-III FREEDOM study results: @26wks. 4mg/day, 63% of patients achieved seizure freedom for POS; 65% of patients with generalized seizures are convulsive seizure free Fycompa is […]Read More

Merck and Pfizer Reports Results of Avelumab in P-III JAVELIN

Shots: The P-III JAVELIN Ovarian 100 study involves assessing of avelumab + and/or following Pt-based carboplatin/paclitaxel CT in 998 patients with LA or metastatic (Stage III or Stage IV) epithelial ovarian cancer, fallopian tube cancer (FTC), or primary peritoneal cancer The study resulted in unmet 1EPs as PFS and has shown no new safety signals with consistent safety profile […]Read More